Long non-coding RNA MALAT1 regulates ovarian cancer cell proliferation, migration and apoptosis through Wnt/β-catenin signaling pathway

被引:8
作者
Guo, C. [1 ]
Wang, X. [1 ,2 ]
Chen, L. -P. [1 ]
Li, M. [1 ]
Li, M. [1 ]
Hu, Y. -H. [1 ]
Ding, W. -H. [1 ]
Wang, X. [1 ,2 ]
机构
[1] Hubei Univ Med, Taihe Hosp, Dept Obstet & Gynecol, Shiyan, Peoples R China
[2] Chongqing Med Univ, Phys Examinat Ctr, Affiliated Hosp 3, Chongqing, Peoples R China
关键词
MALAT1; Ovarian cancer; Proliferation; Invasion; Migration; Cell cycle; Wnt; beta-catenin; PROMOTES PROLIFERATION; COLORECTAL-CANCER; METASTASIS; PROGNOSIS; GROWTH; CHEMORESISTANCE; EXPRESSION; RESISTANCE; INVASION;
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
OBJECTIVE: Long non-coding RNA (LncRNA) MALAT1 is an important regulatory molecule in many diseases, especially in ovarian cancer. We aimed at exploring the function of MALAT1 in ovarian cancer and at clarifying its mechanisms. PATIENTS AND METHODS: The expression level of MALAT1 in ovarian cancer tissues, para-carcinoma tissues and ovarian cancer cell lines were analyzed by Real-time polymerase chain reaction (RT-PCR). The cell proliferation rate was detected by CCK8 assay in SKOV3 and HO8910 cells. Transwell was used to detect the invasion and migration activities in SKOV3 and HO8910 cells. The cell cycle distribution and apoptosis rate were measured by flow cytometry analysis. The expression level of Dvl2, GSK3 beta, beta-catenin and cyclin D1 were detected by RTPCR and Western blot. RESULTS: The relative expression level of MALAT1 was identified to be aberrantly up-regulated in ovarian cancer tissues and cell lines. The high expression level of MALAT1 was associated with poor prognosis in ovarian cancer patients. The down-regulation of MALAT1 inhibited cell proliferation, invasion and migration, arrested cell cycle progression in S phase and induced cell apoptosis in ovarian cancer cell lines. Meanwhile, the down-regulation of MALAT1 decreased the expression level of DVL2, beta-catenin and cyclin D1 and increased the expression level of GSK-3 beta in SKOV3 and HO8910 cells. Moreover, the inhibitory effect of MALAT1 down-regulation in cell invasion and migration was reversed by SKL2001 activating Wnt/beta-catenin signal pathway and enhanced by XAV939 inhibiting Wnt/beta-catenin signal pathway. CONCLUSIONS: MALAT1 was overexpressed in ovarian cancer and associated to the poor prognosis. The down-regulation of MALAT1 inhibited cell proliferation, invasion and migration, arrested cell cycle progression in S phase and induced cell apoptosis by restraining the activation of Wnt/beta-catenin signaling pathway in ovarian cancer cells.
引用
收藏
页码:3703 / 3712
页数:10
相关论文
共 32 条
  • [1] [Anonymous], 2018, ONCOTARGET
  • [2] Long noncoding RNA MALAT1 knockdown reverses chemoresistance to temozolomide via promoting microRNA-101 in glioblastoma
    Cai, Tao
    Liu, Yu
    Xiao, Jie
    [J]. CANCER MEDICINE, 2018, 7 (04): : 1404 - 1415
  • [3] LncRNA-MALAT1 contributes to the cisplatin-resistance of lung cancer by upregulating MRP1 and MDR1 via STAT3 activation
    Fang, Zhixian
    Chen, Wenyu
    Yuan, Zuguo
    Liu, Xinge
    Jiang, Hao
    [J]. BIOMEDICINE & PHARMACOTHERAPY, 2018, 101 : 536 - 542
  • [4] Long noncoding RNA MALAT1 regulates autophagy associated chemoresistance via miR-23b-3p sequestration in gastric cancer
    Hu YiRen
    Yu YingCong
    You Sunwu
    Li Keqin
    Tong Xiaochun
    Chen Senrui
    Chen Ende
    Lin XiZhou
    Chen Yanfan
    [J]. MOLECULAR CANCER, 2017, 16
  • [5] Long non-coding RNA RP11-552M11.4 promotes cells proliferation, migration and invasion by targeting BRCA2 in ovarian cancer
    Huang, Kejin
    Geng, Jiashi
    Wang, Jing
    [J]. CANCER SCIENCE, 2018, 109 (05) : 1428 - 1446
  • [6] Diagnostic Value of the lncRNA NEAT1 in Peripheral Blood Mononuclear Cells of Patients with Sepsis
    Huang, Shuying
    Qian, Kejian
    Zhu, Yuanfang
    Huang, Zikun
    Luo, Qing
    Qing, Cheng
    [J]. DISEASE MARKERS, 2017, 2017
  • [7] Jin Y, 2017, EUR REV MED PHARMACO, V21, P3176
  • [8] Lai XJ, 2018, EUR REV MED PHARMACO, V22, P322, DOI 10.26355/eurrev_201801_14175
  • [9] Li AH, 2017, EUR REV MED PHARMACO, V21, P5618, DOI 10.26355/eurrev_201712_14003
  • [10] Li L, 2017, EUR REV MED PHARMACO, V21, P5610, DOI 10.26355/eurrev_201712_14002